2021-07-01 11:24:41

FDA REVIEWING HWGB’S EBI’S POLIO VACCINE FOR COVID-19 VACCINE EMERGENCY USE

KUALA LUMPUR, 1 JULY 2021 – Ho Wah Genting Berhad (“HWGB” or the “Company”) (Bursa Stock Code: 9601), through its wholly-owned subsidiary HWGB Biotech Sdn Bhd (“HWGB Biotech”), today announced the US Food and Drug Administration (“FDA”) is reviewing E-MO Biology Inc. (“EBI”) submission on the findings of the Phase 4 Clinical Trial for the Emergency Use Authorization (EUA). On 22 June 2021, EBI had submitted the findings of its phase-4 clinical trial to FDA under Emergency Use Authorization (EUA) of polio vaccine to be repurposed as COVID-19 vaccine.
                                                                           
The EUA allowed use of the vaccines during the pandemic when certain criteria are met. The submission is based on the polio vaccine’s high safety and efficacy rate demonstrated in the companies’ Phase 4 clinical study among participants without prior COVID-19 infection. The clinical trial evaluated 300 subjects aged 18 to 80 years old and 100% of the Subjects produced an immune response that recognized protein (RdRp) of both poliovirus and SARS-Cov-2 in their blood samples after vaccination.
 
 ***

Back